Prof. Dr. Murat Binbay'ın akademik çalışmaları — tam metinleri PDF olarak indirebilirsiniz.
In sexually active men resistant to alpha-blockers, water vapour therapy delivered with Rezum produced significantly greater improvement in IPSS at year 1 and preserved sexual function (European Urology Focus, 2026).
A cohort study covering 2005-2024 in the US Veterans Health System showed that the use of active surveillance in low-risk prostate cancer rose from 27% to 93%; in favourable intermediate-risk disease the rate rose from 14% to 61%.
The Frame-to-Outcome (F2O) system developed under the leadership of Cedars-Sinai decomposed the nerve-sparing phase of robotic prostatectomy second by second into surgical gestures and predicted postoperative outcomes with accuracy at the level of a human expert.
The FDA has granted both Breakthrough Therapy and Fast Track designations to 68Ga-NYM096, a CAIX-targeted radiopharmaceutical developed to image clear cell renal cell carcinoma; accuracy of 95.7% was reported in a 24-patient preliminary study presented at ASCO 2026.
In the Alliance A031801 (RADICAL) trial, adding radium-223 to cabozantinib did not improve skeletal event-free survival; the trial was stopped early for futility (Journal of Clinical Oncology, 2026).
In the NRG-GU005 trial, five-session SBRT improved bowel quality of life and the rate of serious urinary adverse events in intermediate-risk prostate cancer; but it did not achieve superiority in three-year disease-free survival and biochemical failure was more frequent.
The AUA/SUO 2026 amendment places PSMA-PET at the centre of biochemical recurrence and metastatic hormone-sensitive disease; risk-based classification and the ADT plus ARPI combination are becoming standard.
ARASEC reported a 71% reduction in the risk of progression and approximately 50% reduction in the risk of mortality with darolutamide plus ADT; ARACOG reported significantly less cognitive decline compared with enzalutamide.
DIRECT-AI, the first national registry to be conducted across the United States, will prospectively measure how the ArteraAI Prostate Test affects treatment choice, physician confidence and long-term oncological outcomes. The first patient was enrolled on 13 August 2026.